CITRASATE® — BETTER CLINICAL & OUTCOMES AND LOWER COST PER SESSION.
Citrasate® is a citrate-based dialysis concentrate that replaces acetic acid with citric acid — a naturally occurring anticoagulant with a long and safe history of use in medicine.
For operators, it delivers two things simultaneously: better patient outcomes and lower operating cost per session.
Both are backed by clinical evidence. Both are achievable from the first session.
USFDA-registered citrate dialysis concentrate. Proven across 30 years of clinical evidence
Up to 55% reduction in heparin requirements
Clinical studies confirm that Citrasate® can significantly reduce — and in some cases eliminate — the need for heparin during treatment. This makes it particularly valuable for patients with bleeding risk, heparin-induced complications, or heparin sensitivity.
Improved dialysis dose (Kt/V)
Citrasate® keeps dialyzer fibres and pores open during treatment, boosting urea reduction and overall treatment efficacy. Clearance increases approximately 1% — a meaningful improvement across a high-volume session load.
Reduced infection rates
The elimination of acetate reduces inflammation at the access site and supports better immune response, leading to fewer dialysis-related infections and less nursing intervention per session.
Lower post-dialysis fatigue and faster recovery
Patients report improved energy levels and fewer post-dialysis complications. For a patient receiving treatment three times per week, this is a meaningful improvement in quality of life.
What Citrasate® delivers for your operation:
THE CLINICAL BENEFITS
THE COST BENEFITS
What Citrasate® delivers for your operation:
• Lower heparin cost per session — up to 55% heparin reduction directly reduces medication spend across every treatment
• Fewer infection-related interventions — lower infection rates mean less nursing time per session and fewer complications to manage
• Available at lower cost than current liquid concentrate — switching to Citrasate® does not add cost; in most cases it reduces it
• Dry format available — significantly reduces freight cost and storage requirements compared to liquid concentrate, particularly for island and remote markets
4 containers of liquid concentrate. 1 container of dry powder mix. Same number of treatments. One quarter of the freight.
USFDA-registered
Citrasate® is registered with the US Food and Drug Administration. Its safety profile is established across over 30 years of clinical use worldwide.
Compatible with all standard haemodialysis machines
Citrasate® Dry can be used with existing dialysis equipment with no additional system monitoring requirements beyond standard treatment protocols.
Available in dry format
Dry format offers significant freight and storage advantages for African and island markets where liquid concentrate logistics add cost and complexity.
SHK Medical supplies Citrasate® at bulk scale across Africa, the Middle East, and island markets.
We handle the logistics so operators do not have to. Supply cycles are planned against your session volume — not a generic schedule.
For operators currently importing liquid concentrate, switching to Citrasate® Dry can meaningfully reduce your freight cost per unit — in addition to the clinical and heparin-cost savings.
IF YOU WANT TO UNDERSTAND WHETHER CITRASATE® IS RIGHT FOR YOUR OPERATION — LET’S TALK.
We can confirm compatibility with your machine fleet and discuss supply at your required volume.
REGULATORY AND CLINICAL CREDENTIALS
UP TO 55%
reduction in heparin requirements. Verified across multiple clinical studies.